Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONS-1045 versus EU- and US-licensed Avastin pharmacokinetic similarity study in healthy male volunteers
NL-OMON41859Active, not recruiting
- Sponsor
- Outlook Therapeutics
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of bevacizumab in cancer, sponsored by Outlook Therapeutics. Primary endpoint: AUC0-inf. Started Dec 2014; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON41859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41859.